ClinicalTrials.gg
RecruitingNCT07673302Updated Aug 6, 2026

Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia

An interventional study of Thalidomide and Hydroxy Urea in Thalassemia, sponsored by Riphah International University. Recruiting at 1 site in Pakistan. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing thalidomide in Thalassemia — 3 open to participants now, 4 under way, none of them phase 3. Thalidomide · Thalassemia.

Planned enrollment
2nd of 10
240 · median 84
Started
2026
with 1 other
No phase
2 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Riphah International University

Among the 10 studies testing thalidomide in Thalassemia, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2026, is one of 2 with no phase, and was the 10th registered.

Thalassemia

252 studies on the registry are indexed under Thalassemia; 45 are open to participants now.

Browse Thalassemia studies →

Open to participants now

3 of the 10 studies testing thalidomide in Thalassemia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About thalidomide

Thalidomide: first FDA approval 1998 (THALOMID), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 29 Thalassemia studies recruiting now, 8 (28%) set no upper age limit and 18 (62%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing thalidomide in Thalassemia, or all of them as a file.
02

Study summary

The aim of this study is to determine the safety and therapeutic effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on beta thalassemia patients. The main objectives of this study are:

  • To determine the therapeutic efficacy of HbF inducers (combination therapy: thalidomide and hydroxyurea) on hemoglobin level and blood transfusion in beta thalassemia patients.
  • To determine the safety of HbF inducers (combination therapy: thalidomide and hydroxyurea) in beta thalassemia patients
  • To determine effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on quality of life of beta thalassemia patients
Read the detailed description

This is a two-arm comparative study. One group is the interventional group, in which all patients will receive thalidomide and hydroxyurea. Low-dose Thalidomide will be administered to patients at a low dose of 0.5 to 4 mg/kg orally every day for 12 months until continuous transfusion-dependency or unacceptable toxicity occurs. The starting dose of hydroxyurea will be 10-20 mg/kg per day. The second group will be the control group for blood transfusion.

In the intervention group, 114 confirmed diagnoses of beta thalassemia ascertained by Hemoglobin Electrophoresis or HPLC report performed pre-transfusion or genetic testing profile (comprising PCR or HBB gene sequencing) suggestive of β-thalassemia syndrome will be included. To assess the therapeutic efficacy of HbF inducers (combination therapy: thalidomide and hydroxyurea), the number of blood transfusions and hemoglobin level will be assessed as per the given schedule.

. Adverse events will be recorded at each follow-up to assess the safety of the therapy. The patient/guardian/parent will be specifically asked about paresthesia, rash, constipation, unexplained infections, bleeding symptoms, headache, syncope, focal weakness, and behavioral changes. All participants will be asked to report any adverse reactions and will be questioned about adverse events during the study visit. EORTC QLQ C-30 URDU version, a self-administered questionnaire, will be filled by each participant at baseline and 6 months.

03

Conditions studied

  • Thalassemia

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of Beta thalassemia Major (BTM) ascertained by Electrophoresis or HPLC report performed pre-transfusion or genetic testing profile (comprising PCR or HBB gene sequencing) suggestive of β-thalassemia syndrome.
  • All ages and both genders will be included
  • Written

Exclusion criteria

Exclusion criteria:

  • Pregnancy or unwilling to follow or planning conception (Enrolled female patients will be strictly advised to avoid pregnancy during the study period and until 6 months after thalidomide withdrawal.
  • Hemoglobinopathies other than beta thalassemia
  • History of neurological problems
  • Inability to regularly follow up
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • No intervention
    Blood transfusion Group

    Control group will be on regular blood transfusion and iron chelation therapy

  • Experimental
    HbF inducers

    All patients will receive thalidomide and hydroxyurea. Low dose Thalidomide will be administered to patients at a low dose of 0.5 to 4 mg/kg orally every day for 12 months until continuous transfusion-dependency or unacceptable toxicity occurred. The starting dose of hydroxyurea will be 10-20 mg/kg per day.

    Drug: Thalidomide · Drug: Hydroxy Urea

Interventions

  • Tab Thalidomide 0.5 to 4 mg/kg orally every day for 12 months

    Also known as: Thalido

  • Tab Hydroxyurea 10-20 mg/kg per day for 12 months

    Also known as: Hydrea

06

What researchers measure

Primary outcomes

  1. Improvement in the hemoglobin level

    To evaluate the Improvement in Hemoglobin level, response criteria are defined as follows: Major response, an elevation in total Hb level of ≥2 g/dL Minor response, an elevation in total Hb level of 1 to 2 g/dL, or Hb not substantially increased (\<1 g/dL) but the patients achieve Hb\>7 g/L No response, an elevation in total Hb level of \<1 g/dL

    Time frame: 6 months

  2. Decrease in transfusion requirement

    To evaluate the decrease in transfusion requirement, response criteria are defined as follows: Major response: reduce transfusion requirements by ≥25% after 6 months of therapy compared to baseline. Minor response: reduce transfusion requirement by \<25 % after 6 months of therapy, No response: same blood transfusion requirement as baseline

    Time frame: 6 months

Secondary outcomes

  1. Serum Bilirubin levels

    0.2- 1.1 mg/dL Normal \>1.1- 3 mg/dL Mild derangement \>3 mg/dL Severe derangement

    Time frame: 1 year

  2. Change in ALT levels

    ALT levels range: 0- 42 U/L Normal \>42-126 U/L Mild severity \>126- 420 U/L Moderate severity \>420 U/L severe

    Time frame: 1 year

  3. Change in serum creatinine levels

    Serum creatinine 0.2 - 1.1 mg/dL Normal \>1.1- 1.5 mg/dL Mild severity \>1.5- 3.0 mg/dL Moderate severity \>3 mg/dL Severe

    Time frame: 1 year

  4. Assess Quality of life by using EORTC QLQ-C30

    EORTC QLQ C-30 URDU version, a self-administered questionnaire, will be filled by each participant at baseline and 6 months. Functional/Global: 100 = perfect function. 0 = no function. 10-point change = clinically meaningful. Symptoms: 0 = no symptoms. 100 = maximum symptoms 10-point increase = worse symptom burden.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Chen JM, Zhu WJ, Liu J, Wang GZ, Chen XQ, Tan Y, Xu WW, Qu LW, Li JY, Yang HJ, Huang L, Cai N, Wang WD, Huang K, Xu JQ, Li GH, He S, Luo TY, Huang Y, Liu SH, Wu WQ, Lu QY, Zhou MG, Chen SY, Li RL, Hu ML, Huang Y, Wei JH, Li JM, Chen SJ, Zhou GB. Safety and efficacy of thalidomide in patients with transfusion-dependent beta-thalassemia: a randomized clinical trial. Signal Transduct Target Ther. 2021 Nov 18;6(1):405. doi: 10.1038/s41392-021-00811-0. PubMed 34795208 ↗
  • Ali Z, Ismail M, Rehman IU, Rani GF, Ali M, Khan MTM. Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent beta-thalassemia: results from Thal-Thalido study. Sci Rep. 2023 Aug 21;13(1):13592. doi: 10.1038/s41598-023-40849-4. PubMed 37604857 ↗
  • Tuo Y, Li Y, Li Y, Ma J, Yang X, Wu S, Jin J, He Z. Global, regional, and national burden of thalassemia, 1990-2021: a systematic analysis for the global burden of disease study 2021. EClinicalMedicine. 2024 May 6;72:102619. doi: 10.1016/j.eclinm.2024.102619. eCollection 2024 Jun. PubMed 38745964 ↗
  • Lu Y, Wei Z, Yang G, Lai Y, Liu R. Investigating the Efficacy and Safety of Thalidomide for Treating Patients With ss-Thalassemia: A Meta-Analysis. Front Pharmacol. 2022 Jan 11;12:814302. doi: 10.3389/fphar.2021.814302. eCollection 2021. PubMed 35087410 ↗
  • Shah S, Sheth R, Shah K, Patel K. Safety and effectiveness of thalidomide and hydroxyurea combination in beta-thalassaemia intermedia and major: a retrospective pilot study. Br J Haematol. 2020 Feb;188(3):e18-e21. doi: 10.1111/bjh.16272. Epub 2019 Nov 11. No abstract available. PubMed 31710694 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 18 interventional studies with no phase under Thalassemia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 87. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 29, 2026
StartActual
Jun 20, 2026
Primary completionEst.
Jun 19, 2027
CompletionEst.
Jun 19, 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07673302
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Jun 20, 2026
Primary completion
Jun 19, 2027 (estimated)
Completion
Jun 19, 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Fariha Sardar, MBBS, FCPS
Contact
doc.fariha@yahoo.com
+923335517877
Fariha Sardar, MBBS, FCPS
Contact
afzaal2kmt20@gamil.com
+923350941494
Fariha Sardar, MBBS, FCPS
principal investigator · Riphah International University, Rwp

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Thalidomide · Hydroxyurea

Start the discussion